This dynamic presentation is from our October 2020 edition of Psychedelic Capital. You can get FREE access to recordings here using discount code ‘PSYCAP’! To learn more about our amazing Psychedelic Capital sponsors, click here!

 

The month of October has observed progress of seismic proportions in the psychedelic industry. From Cybin Corp. closing Canada’s largest ever go-public financing in the psychedelic sector to Numinus announcing the completion of their first legal psilocybin mushroom harvest, a lot has been happening–and quickly. It certainly seems like Canada’s turn to strike back after United States based Compass Pathways has been dominating the headlines. We were lucky enough to have Numinus as a sponsor at our last psychedelic capital event. Here are three key takeaways from their engaging presentation. 

Key Takeaway #1: Huge Regulatory Strides Are Being Made for Psychedelic Medicine

 

Despite decades of prohibition, psychedelics have made significant progress in regards to regulatory policies. Breakthrough therapy status for psilocybin and MDMA continues to point to the real ground swell and tide turning the public is witnessing from the FDA. Both these drugs are projected to be legal for therapy as soon as 2021. This has opened massive investment opportunities, as clearly spotlighted by Compass Pathways going public with over a billion dollar market cap. 


Even more recently, we have seen Canada’s health minister approve four Canadian’s with terminal cancer for psilocybin therapy–a monumental milestone for psychedelic medicine! Such policy advancements are rapidly paving the way forward for a brighter future with more robust mental health treatments for the world at large.

Key Takeaway #2: The Numinus Team is Bold, Experienced & Innovative

 

One of the key takeaways from the Numinus Inc presentation at Psychedelic Capital is their dynamic clinical leadership team. Their highly experienced medical director, Dr. Devon Christie, brings deep experience with MDMA and ketamine assisted psychotherapy (through MAPS USA). Dr. Evan Wood, another key Numinus player, has published over 500 scientific articles and made major contributions to the establishment of innovative policy and therapeutic programs. In fact, Dr. Wood was directly responsible for getting cannabis reform on prime minister Justin Trudeau’s party platform.

Another key Numinus player worth mentioning is world renowned addiction and palliative care physician, Dr. Gabor Maté. With over a decade of experience working with patients challenged by drug addiction and mental illness in Vancouver’s Downtown Eastside, Dr. Maté brings a deep and robust perspective to his work at Numinus. Several other key players and members of Numinus’ leadership team and advisory board can be found on their website

Numinus psychedelic capital mushroom psilocybin therapy legal

Key Takeaway #3: Numinus is in it for the Long Run & the Right Reasons

 

Perhaps one of the most important takeaways from Numinus’ talk at Psychedelic Capital is their dedication to setting a high bar for success and playing the long game for the right reasons. While the “green rush” in the cannabis sector certainly drew many short-term investors looking to make a quick buck, the team at Numinus realizes the immense benefits their long-term strategy has, not only for their investors but for the world at large. The Numinus team is embracing the full complexity of psychedelic medicine and working hard to create a safe, effective protocol from providing the psychedelic substance to mindfully establishing a conducive set and setting for patients. 


Numius CEO, Payton Nyquvest, stated that the only way to accomplish this is through an implementation science agenda. He stated that, “we know that these medications will be approved, but it’s still a ways away. It involves open label phase 1 clinical trials allowing us to beta test, refine and evolve a business model aimed at providing safe and effective psychedelic assisted psychotherapy.” 

 

Nyquvest goes on to state that, “this gives us the unique opportunity to marry basic science and clinical research. Our Health canada license allows us to use the full suite of psychedelic substances. MDMA and psilocybin are both at the forefront of the movement.”

 

By paying close attention to the full spectrum of psychedelic therapy, including the supportive practices around prep and integration, the Numinus team is certainly projected to continue their upward trajectory in this emerging space. 

Numinus psychedelic capital mushroom psilocybin therapy legal

Looking Ahead for the Numinus Inc Team

 

As the psychedelic renaissance amples forth, the Numinus team continues to pioneer the charge at the forefront of the industry with their skilled team of scientists and researchers. From the significant regulatory progress these compounds have been making at the policy level to the skilled scientific team and clear vision held by the team at Numinus, this is one company sure to make a massive impact on the emerging sector. 

Make sure to catch this great talk and many more at our last Psychedelic Capital event here by using the code “PSYCAP” for free access!

Numinus psychedelic capital mushroom psilocybin therapy legal